Table 2.
IGF2BP1 expression in human cancers
| Cancer | Method | Incidence | References |
|---|---|---|---|
| Breast | RT-PCR | 59 % (69/118) | [109] |
| Ovarian carcinomas | IHC | 69 % (73/106) | [13] |
| Ovarian | IHC | Not done (associated with MDR1) | [56] |
| Testis | IHC | 90 % (30/33) | [26] |
| Brain tumors (various) | RT-PCR | 55 % (28/51) | [110] |
| Melanoma | IHC | 34 % (13/38) | [111] |
| Non-small cell lung | RT-PCR | 27 % (4/11) | [110] |
| Pancreatic | Northern | 33 % (5/15) | [112] |
| Colon, lung, ovarian | IHC | >60 % | [61] |
| Colon | IHC, RT-qPCR | 50 % (36/78), 59 % (46/78) | [52] |
| Colorectal | RT-PCR | 81 % (17/21) | [51] |
| Mesenchymal | RT-PCR | 65 % (28/43) | [113] |
| Hodgkin lymphoma | IHC | 94 % (101/108) | [78] |
| B cell lymphomas (various) | IHC | 69 % (458/661) | [78] |